May 6 |
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript
|
May 4 |
Ascendis Pharma A/S (ASND) Q1 2024 Earnings Call Transcript
|
May 4 |
Ascendis Pharma First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
May 2 |
Ascendis Pharma reports Q1 results
|
May 2 |
Ascendis Pharma Reports First Quarter 2024 Financial Results
|
May 1 |
Ascendis Pharma Q1 2024 Earnings Preview
|
Apr 26 |
Looking Into Ascendis Pharma's Recent Short Interest
|
Apr 25 |
Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024
|
Apr 24 |
United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
|
Apr 3 |
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
|